文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

解偶联蛋白2过表达通过抑制活性氧产生和炎症减轻脓毒症心肌损伤

[Uncoupling protein 2 overexpression alleviates sepsis-induced myocardial injury via inhibiting reactive oxygen species production and inflammation].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论大鼠CLP脓毒症模型中,心肌过表达UCP2可降低ROS、心肌酶和炎症因子,36小时生存率从30.0%提高至60.0%。

UCP2组心肌注射AAV-UCP2(滴度1×10^12 v.g/mL,每点10 μL,共60 μL),3周后行CLP。CLP后24小时,UCP2过表达组较CLP组和AAV组ROS产生显著减少,LDH、CK、cTnI、TNF-α、IL-6均显著降低(均P<0.01)。Kaplan-Meier生存曲线显示CLP后36小时生存率仅30.0%,UCP2过表达组提高至60.0%(与CLP组、AAV组比较均P<0.05)。结论提示UCP2过表达可通过减少ROS和抑制炎症减轻脓毒症心肌损伤并改善生存率。

要点

  • 在SD大鼠CLP脓毒症模型中,心肌过表达UCP2使36小时生存率从30.0%提高至60.0%(P<0.05)。
  • UCP2过表达组ROS产生较CLP组和AAV组显著减少(A值:1.03±0.10 vs. 1.81±0.13、1.67±0.08,均P<0.01)。
  • UCP2过表达组cTnI为199.79±18.27 ng/L,低于CLP组的241.88±14.32 ng/L和AAV组的243.33±23.79 ng/L(均P<0.01)。
  • UCP2过表达组TNF-α为385.71±20.09 ng/L,低于CLP组的488.92±26.92 ng/L和AAV组的489.03±33.37 ng/L(均P<0.01)。
  • AAV组与CLP组在UCP2表达、ROS、心肌酶、炎症因子及生存率方面均无显著差异。

适用人群与场景

  • UCP2组和AAV组分别经心肌注射AAV-UCP2或AAV病毒,3周后行盲肠结扎穿孔(CLP)制备脓毒症模型。

诊断标准与关键阈值

  • CLP后24小时评估模型是否成功:大鼠表现为毛发僵硬、眼鼻口分泌物增多、脓尿、稀便和呼吸困难;开腹见盲肠紫黑色、肠腔周围脓性渗出。
  • 荧光显微镜下冰冻切片见绿色荧光提示病毒转染成功;Western blotting检测UCP2蛋白表达。

处置流程与药物剂量

  • 第一步:UCP2组于心肌注射AAV-UCP2(滴度1×10^12 v.g/mL,每点10 μL,共60 μL),3周后行CLP。
  • 第二步:AAV组于心肌转染AAV病毒,3周后行CLP。
  • 第三步:CLP后24小时检测UCP2蛋白表达、ROS产生、血清心肌标志物和炎症因子。
  • 第四步:Kaplan-Meier生存曲线观察CLP后36小时生存率。
  • 原文未提及临床药物剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • CLP后24小时大鼠出现毛发僵硬、眼鼻口分泌物增多、脓尿、稀便和呼吸困难,提示脓毒症模型制备成功。
  • 开腹见盲肠紫黑色、肠腔周围脓性渗出,提示CLP模型成功。
  • 原文未提及其他红旗征或需立刻处理的临床情况。

研究设计与关键结果

  • CLP组UCP2表达高于Sham组(UCP2/β-tubulin:1.53±0.06 vs. 1,P<0.01);UCP2组UCP2表达进一步高于AAV组(1.96±0.22 vs. 1.59±0.07,P<0.01)。
  • UCP2过表达组ROS产生较CLP组和AAV组显著减少(A值:1.03±0.10 vs. 1.81±0.13、1.67±0.08,均P<0.01)。
  • UCP2过表达组LDH、CK、cTnI、TNF-α、IL-6均显著低于CLP组和AAV组(均P<0.01),具体数值见原文。
  • CLP后36小时生存率:CLP组30.0%,AAV组30.0%,UCP2组60.0%(与CLP组、AAV组比较均P<0.05);AAV组与CLP组无显著差异。

证据类型、等级与局限

  • 证据类型:动物实验(RCT设计,随机分组),非临床研究。
  • 局限:样本量小(每组10只)、单中心动物实验、观察时间短(36小时)、种属差异,不能直接外推至临床患者。

对床旁实践的改变

  • 该研究为动物实验,不能直接改变急诊/ICU临床实践;UCP2过表达目前不是临床可用治疗手段。
  • 适用人群:仅限SD大鼠CLP脓毒症模型;不适用于临床脓毒症患者。
  • 常见陷阱:不可将动物实验中的生存率、心肌酶或炎症因子数值当作临床决策阈值或治疗目标。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate whether the overexpression of uncoupling protein 2 (UCP2) can protect myocardium from sepsis by inhibiting the production of reactive oxygen species (ROS) and inflammatory response.

METHODS: Forty Sprague-Dawley rats were divided into four groups according to random number table method (n = 10): sham transfection and sham surgery group (Sham group), sham transfection and cecal ligation and perforation (CLP) group (CLP group), simple adeno-associated virus (AAV) transfection surgery group (AAV group), and UCP2 overexpression surgery group (UCP2 group). In UCP2 group, UCP2 adeno-associated virus (AAV-UCP2; titer 1×1012 v.g/mL, 10 μL per site, 60 μL in total) was injected into myocardium, and CLP was performed 3 weeks later. In AAV group, the myocardium was transfected with AAV virus and CLP was performed 3 weeks later. Twenty-four hours after modeling, whether the model was successfully prepared was evaluated. The transfection effect of AAV virus on the frozen sections of myocardial tissue was observed under fluorescence microscope, the expression of UCP2 protein was detected by Western blotting, ROS production was detected by dihydroethidine (DHE) staining, and serum myocardial markers and inflammatory cytokines were detected by enzyme linked immunosorbent assay (ELISA).

RESULTS: Twenty-four hours after CLP, the rats showed stiff hair, increased secretions from eyes, nose and mouth, and symptoms of pyuria, loose stools, and dyspnea. After laparotomy, the cecum showed purple and black, and there was purulent exudation around the intestinal cavity. The virus was successfully transfected on frozen section under the fluorescence microscope (the site of the transfection was green fluorescence), and further Western blotting revealed that the expression of UCP2 in the CLP group was higher than that in the Sham group (UCP2/β-tubulin: 1.53±0.06 vs. 1, P < 0.01). Compared with the AAV group, UCP2 expression was further increased in the UCP2 group (UCP2/β-tubulin: 1.96±0.22 vs. 1.59±0.07, P < 0.01). Under the fluorescence microscope, ROS production in the CLP and AAV groups were found significantly increased compared with that in the Sham group; when UCP2 was overexpressed, ROS production were significantly decreased compared with the CLP and AAV groups (A value: 1.03±0.10 vs. 1.81±0.13, 1.67±0.08, both P < 0.01). ELISA showed that compared with the Sham group, the levels of lactate dehydrogenase (LDH), creatine kinase (CK), cardiac troponin I (cTnI), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were significantly increased in the CLP and AAV groups; when UCP2 was overexpressed, the above myocardial enzymes and inflammatory cytokines secretion were significantly decreased compared with the CLP group and AAV group [LDH (ng/L): 48.97±1.04 vs. 56.85±1.36, 57.08±1.54; CK (ng/L): 235.23±20.33 vs. 306.34±25.93, 304.76±25.29; cTnI (ng/L): 199.79±18.27 vs. 241.88±14.32, 243.33±23.79; TNF-α (ng/L): 385.71±20.09 vs. 488.92±26.92, 489.03±33.37; IL-6 (ng/L): 121.12±7.61 vs. 159.07±17.65, 157.61±15.13; all P < 0.01]. Kaplan-Meier survival curve showed that the survival rate of rats 36 hours after CLP was only 30.0%. When UCP2 overexpressed, the survival rate was significantly higher than that of the CLP group and AAV group (60.0% vs. 30.0%, 30.0%, both P < 0.05). There was no significant difference between the AAV group and CLP group.

CONCLUSIONS: UCP2 overexpression can reduce myocardial injury and improve the survival rate of septic rats by reducing ROS production and inhibiting inflammatory reaction in septic myocardium.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Geng Z, Luo S, Li G, et al. [Uncoupling protein 2 overexpression alleviates sepsis-induced myocardial injury via inhibiting reactive oxygen species production and inflammation]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33463495. doi:10.3760/cma.j.cn121430-20200415-00298

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。